Skip to main content
Psych Congress  

Is Increased Severity of Major Depressive Disorder Associated With Incremental Economic Burden in Privately Insured US Patients With Treatment Resistant Depression?

Authors  

Dominic  Pilon, MA – Analysis Group, Inc.; Holly Szukis, MPH – Janssen Scientific Affairs, LLC; John Sheehan, PhD, MBA, RPh – Janssen Scientific Affairs, LLC; Laura  Morrison, MPH – Analysis Group, Inc.; Maryia  Zhdanava, MA – Analysis Group, Inc.; Patrick  Lefebvre, MA – Analysis Group, Inc.; Kruti  Joshi, MPH – Janssen Scientific Affairs, LLC

Sponsor  
Janssen Scientific Affairs, LLC

Background: Among patients with major depressive disorder (MDD), those with treatment-resistant depression (TRD) have a higher economic burden. However, healthcare resource utilization (HRU) and costs may vary by MDD severity in patients with TRD.

Objectives: To compare treatment patterns, HRU and costs of TRD by MDD severity.

Methods: A claims-based algorithm identified patients with TRD in a US database of privately insured employees and dependents (OptumHealth Care Solutions, Inc; 01/2010-03/2015). Patients with TRD were stratified into mild, moderate and severe cohorts based on the information in the last observed MDD ICD-9-CM code. HRU and costs of moderate and severe cohorts were compared to those of the mild control cohort using regression models adjusted for patient baseline characteristics. Treatment patterns were compared.

Results: Among 6,411 patients with TRD, 455 (7.1%) were identified as mild, 2,153 (33.6%) as moderate and 1,455 (22.7%) as severe. Pharmacotherapy use was similar across cohorts. In terms of all-cause HRU, moderate and severe patients compared to mild had 45% and 150% more inpatient admissions, 65% and 164% more inpatient days, 18% and 54% more emergency department visits and 8% and 10% more outpatient visits per-patient-per-year, respectively (all p<0.05). The magnitude of differences in mental-health and depression-related HRU among moderate and severe versus mild patients was even greater. The incremental all-cause HRU resulted in all-cause total healthcare cost differences of $3,455 in moderate and $5,150 in severe versus mild patients, respectively (per-patient-per-year; all p<0.05).

Conclusions: Increased MDD severity is associated with incremental economic burden in patients with TRD.

Back to Top